Fluoride Gel |
Gel-Kam; NeutraCare Gel; Phos-Flur; PreviDent Gel; Stan-Gard Gel; Stop Gel; Thera-Flur-N |
Clinical Trial: DAPHNE (Duodopa in Advanced Parkinson''s: Health Outcomes & Net Economic Impact).
DAPHNE (Duodopa in Advanced Parkinson’s: Health Outcomes & Net Economic Impact).
This study is not yet open for patient recruitment.
Verified by Solvay Pharmaceuticals July 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| advanced idiopathic Parkinson''''s disease | Drug: levodopa/carbidopa in an intestinal gel formulation | Phase IV |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Long-Term Health Economics Study of Intraduodenal Levodopa (Duodopa®) in Routine Care for Patients with Advanced Idiopathic Parkinson’s Disease with Severe Motor Fluctuations and Hyper-/Dyskinesia.
Eligibility
Inclusion Criteria:
- advanced idiopathic Parkinson''''s disease
Exclusion Criteria:
- other diseases which might influence compliance or participation in the study
Location and Contact Information
Sweden
Site 1, Stockholm, Sweden
Global Clinical Director Solvay, Study Director, Solvay Pharmaceuticals
More Information
Last Updated: August 31, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00141518
Health Authority: Sweden: Medical Products Agency
ClinicalTrials.gov processed this record on 2005-09-06
Resources
- Fluoride Gel (Drug Digest)
- Gel-Kam (Drug Digest)

Not Signed In -


